Trial Outcomes & Findings for Effect of Steroid for the Postoperative Swelling After Orthognathic Surgery (NCT NCT01431014)
NCT ID: NCT01431014
Last Updated: 2014-03-21
Results Overview
Measure of facial swelling will be performed using 3-dimensional photogrammetry. The 3d photo acquisition is non-invasive without radiation concern. The images will be taken before and after surgery to measure and compare the degree of facial swelling. Side effects from the steroid use are expected to be low under normal clinical dosage, but will also be monitored. Symptoms of wound infection, psychosis, and prolonged wound healing will be studied. There should be no long term complication, since the steroid use is one single dose.
COMPLETED
PHASE4
56 participants
1 year
2014-03-21
Participant Flow
Participant milestones
| Measure |
Dexamethasone"High-dose"
15mg
Dexamethasone"high-dose" : 15 mg
|
Dexamethasone"Low-dose"
5mg
Dexamethasone"low-dose" : 5mg
|
|---|---|---|
|
Overall Study
STARTED
|
34
|
34
|
|
Overall Study
COMPLETED
|
31
|
25
|
|
Overall Study
NOT COMPLETED
|
3
|
9
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Effect of Steroid for the Postoperative Swelling After Orthognathic Surgery
Baseline characteristics by cohort
| Measure |
Dexamethasone"High-dose"
n=31 Participants
15mg
Dexamethasone"high-dose" : 15 mg
|
Dexamethasone"Low-dose"
n=25 Participants
5mg
Dexamethasone"low-dose" : 5mg
|
Total
n=56 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
1 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
30 Participants
n=99 Participants
|
20 Participants
n=107 Participants
|
50 Participants
n=206 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Age, Continuous
|
23.16 years
STANDARD_DEVIATION 4.19 • n=99 Participants
|
20.92 years
STANDARD_DEVIATION 4.79 • n=107 Participants
|
22.16 years
STANDARD_DEVIATION 4.6 • n=206 Participants
|
|
Sex: Female, Male
Female
|
15 Participants
n=99 Participants
|
13 Participants
n=107 Participants
|
28 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
16 Participants
n=99 Participants
|
12 Participants
n=107 Participants
|
28 Participants
n=206 Participants
|
|
Region of Enrollment
Taiwan
|
31 participants
n=99 Participants
|
25 participants
n=107 Participants
|
56 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: 1 yearMeasure of facial swelling will be performed using 3-dimensional photogrammetry. The 3d photo acquisition is non-invasive without radiation concern. The images will be taken before and after surgery to measure and compare the degree of facial swelling. Side effects from the steroid use are expected to be low under normal clinical dosage, but will also be monitored. Symptoms of wound infection, psychosis, and prolonged wound healing will be studied. There should be no long term complication, since the steroid use is one single dose.
Outcome measures
| Measure |
Dexamethasone"High-dose"
n=31 Participants
15mg Dexamethasone"high-dose" : 15 mg
|
Dexamethasone"Low-dose"
n=25 Participants
5mg Dexamethasone"low-dose" : 5 mg
|
|---|---|---|
|
Effect of Perioperative Steroid for the Postoperative Swelling After Orthognathic Surgery
36 hours postoperatively
|
167.06 ml
Standard Deviation 55.93
|
190.73 ml
Standard Deviation 78.74
|
|
Effect of Perioperative Steroid for the Postoperative Swelling After Orthognathic Surgery
1week postoperatively
|
61.39 ml
Standard Deviation 30.14
|
57.62 ml
Standard Deviation 36.13
|
|
Effect of Perioperative Steroid for the Postoperative Swelling After Orthognathic Surgery
1month postoperatively
|
29.85 ml
Standard Deviation 19.40
|
19.34 ml
Standard Deviation 16.56
|
Adverse Events
Dexamethasone"Low-dose"
Dexamethasone"High-dose"
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place